1921
Volume 98 Number 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Chagas disease, caused by , is transmitted by insect vectors through transfusions, transplants, insect feces in food, and from mother to child during gestation. Congenital infection could perpetuate Chagas disease indefinitely, even in countries without vector transmission. An estimated 30% of infected persons will develop lifelong, potentially fatal, cardiac or digestive complications. Treatment of infants with benznidazole is highly efficacious in eliminating infection. This work evaluates the costs of maternal screening and infant testing and treatment of Chagas disease in the United States. We constructed a decision-analytic model to find the lower cost option, comparing costs of testing and treatment, as needed, for mothers and infants with the lifetime societal costs without testing and the consequent morbidity and mortality due to lack of treatment or late treatment. We found that maternal screening, infant testing, and treatment of Chagas disease in the United States are cost saving for all rates of congenital transmission greater than 0.001% and all levels of maternal prevalence above 0.06% compared with no screening program. Newly approved diagnostics make universal screening cost saving with maternal prevalence as low as 0.008%. The present value of lifetime societal savings due to screening and treatment is about $634 million saved for every birth year cohort. The benefits of universal screening for as part of routine prenatal testing far outweigh the program costs for all U.S. births.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.17-0818
2018-06-08
2018-11-19
Loading full text...

Full text loading...

/deliver/fulltext/14761645/98/6/tpmd170818.html?itemId=/content/journals/10.4269/ajtmh.17-0818&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO), 2015. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec 90: 3343.
  2. Bern C, , 2015. Chagas’ disease. N Engl J Med 373: 456466.
  3. Bern C, Kjos S, Yabsley MJ, Montgomery SP, , 2011. Trypanosoma cruzi and Chagas’ disease in the United States. Clin Microbiol Rev 24: 655681.
  4. Bern C, Montgomery SP, , 2009. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 49: e52e54.
  5. Dorn PL, Perniciaro L, Yabsley MJ, Roellig DM, Balsamo G, Diaz J, Wesson D, , 2007. Autochthonous transmission of Trypanosoma cruzi, Louisiana. Emerg Infect Dis 13: 605607.
  6. Rassi A, Jr Rassi A, Marin-Neto JA, ., , 2010. Chagas disease. Lancet 375: 13881402.
  7. Organización Panamericana de la Salud, 2006. Estimación Cuantitativa de la Enfermedad de Chagas en las Américas. Washington, DC: Organización Panamericana de la Salud.
  8. Buekens P, Almendares O, Carlier Y, Dumonteil E, Eberhard M, Gamboa-Leon R, James M, Padilla N, Wesson D, Xiong X, , 2008. Mother-to-child transmission of Chagas’ disease in North America: why don’t we do more? Matern Child Health J 12: 283286.
  9. Schenone H, Gaggero M, Sapunar J, Contreras MC, Rojas A, , 2001. Congenital Chagas disease of second generation in Santiago, Chile. Report of two cases. Rev Inst Med Trop São Paulo 43: 231232.
  10. Carlier Y, Torrico F, Sosa-Estani S, Russomando G, Luquetti A, Freilij H, Albajar Vinas P, , 2011. Congenital Chagas disease: recommendations for diagnosis, treatment and control of newborns, siblings and pregnant women. PLoS Negl Trop Dis 5: e1250.
  11. Requena-Mendez A, Aldasoro E, de Lazzari E, Sicuri E, Brown M, Moore DA, Gascon J, Munoz J, , 2015. Prevalence of Chagas disease in Latin-American migrants living in Europe: a systematic review and meta-analysis. PLoS Negl Trop Dis 9: e0003540.
  12. Sicuri E, Munoz J, Pinazo MJ, Posada E, Sanchez J, Alonso PL, Gascon J, , 2011. Economic evaluation of Chagas disease screening of pregnant Latin American women and of their infants in a non endemic area. Acta Trop 118: 110117.
  13. Hotez PJ, Dumonteil E, Betancourt Cravioto M, Bottazzi ME, Tapia-Conyer R, Meymandi S, Karunakara U, Ribeiro I, Cohen RM, Pecoul B, , 2013. An unfolding tragedy of Chagas disease in North America. PLoS Negl Trop Dis 7: e2300.
  14. Bern C, 2007. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 298: 21712181.
  15. Centers for Disease Control and Prevention, 2012. Congenital transmission of Chagas disease—Virginia, 2010. MMWR Morb Mortal Wkly Rep 61: 477479.
  16. Torrico F, Alonso-Vega C, Suarez E, Rodriguez P, Torrico MC, Dramaix M, Truyens C, Carlier Y, , 2004. Maternal Trypanosoma cruzi infection, pregnancy outcome, morbidity, and mortality of congenitally infected and non-infected newborns in Bolivia. Am J Trop Med Hyg 70: 201209.
  17. Hanford EJ, Zhan FB, Lu Y, Giordano A, , 2007. Chagas disease in Texas: recognizing the significance and implications of evidence in the literature. Soc Sci Med 65: 6079.
  18. Viotti R, Vigliano C, Lococo B, Alvarez MG, Petti M, Bertocchi G, Armenti A, , 2009. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther 7: 157163.
  19. Moscatelli G, Moroni S, Garcia-Bournissen F, Ballering G, Bisio M, Freilij H, Altcheh J, , 2015. Prevention of congenital Chagas through treatment of girls and women of childbearing age. Mem Inst Oswaldo Cruz 110: 507509.
  20. Alvarez MG, Vigliano C, Lococo B, Bertocchi G, Viotti R, , 2017. Prevention of congenital Chagas disease by benznidazole treatment in reproductive-age women. An observational study. Acta Trop 174: 149152.
  21. Morillo CA, 2015. Randomized trial of benznidazole for chronic Chagas’ cardiomyopathy. N Engl J Med 373: 12951306.
  22. Edwards MS, Rench MA, Todd CW, Czaicki N, Steurer FJ, Bern C, Montgomery SP, , 2015. Perinatal screening for Chagas disease in southern Texas. J Pediatric Infect Dis Soc 4: 6770.
  23. Di Pentima MC, Hwang LY, Skeeter CM, Edwards MS, , 1999. Prevalence of antibody to Trypanosoma cruzi in pregnant Hispanic women in Houston. Clin Infect Dis 28: 12811285.
  24. Garcia MN, Woc-Colburn L, Aguilar D, Hotez PJ, Murray KO, , 2015. Historical perspectives on the epidemiology of human Chagas disease in Texas and recommendations for enhanced understanding of clinical Chagas disease in the southern United States. PLoS Negl Trop Dis 9: e0003981.
  25. Cantey PT, 2012. The United States Trypanosoma cruzi infection study: evidence for vector-borne transmission of the parasite that causes Chagas disease among United States blood donors. Transfusion 52: 19221930.
  26. Verani JR, Montgomery SP, Schulkin J, Anderson B, Jones JL, , 2010. Survey of obstetrician-gynecologists in the United States about Chagas disease. Am J Trop Med Hyg 83: 891895.
  27. Rendell VR, 2015. Trypanosoma cruzi-infected pregnant women without vector exposure have higher parasitemia levels: implications for congenital transmission risk. PLoS One 10: e0119527.
  28. Carlier Y, Sosa-Estani S, Luquetti AO, Buekens P, , 2015. Congenital Chagas disease: an update. Mem Inst Oswaldo Cruz 110: 363368.
  29. Norman FF, Lopez-Velez R, , 2014. Mother-to-child transmission of Trypanosoma cruzi infection (Chagas disease): a neglected problem. Trans R Soc Trop Med Hyg 108: 388390.
  30. Shah V, 2014. Field evaluation of the InBios Chagas detect plus rapid test in serum and whole-blood specimens in Bolivia. Clin Vaccine Immunol 21: 16451649.
  31. Egüez KE, Alonso-Padilla J, Terán C, Chipana Z, García W, Torrico F, Gascon J, Lozano-Beltran D-F, Pinazo M-J, , 2017. Rapid diagnostic tests duo as alternative to conventional serological assays for conclusive Chagas disease diagnosis. PLoS Negl Trop Dis 11: e0005501.
  32. Moyer VA, , 2013. Screening for HIV: U.S. preventive services task force recommendation statement. Ann Intern Med 159: 5160.
  33. Delaney KP, Branson BM, Uniyal A, Phillips S, Candal D, Owen SM, Kerndt PR, , 2011. Evaluation of the performance characteristics of 6 rapid HIV antibody tests. Clin Infect Dis 52: 257263.
  34. Boadu R, Darko G, Nortey P, Akweongo P, Sarfo B, , 2016. Assessing the sensitivity and specificity of first response HIV-1–2 test kit with whole blood and serum samples: a cross-sectional study. AIDS Res Ther 13: 9.
  35. Barnett JC, Berchick ER, , 2017. Health Insurance Coverage in the United States: 2016. Washington, DC: U.S. Government Printing Office.
  36. Gebrekristos HT, Buekens P, , 2014. Mother-to-child transmission of Trypanosoma cruzi. J Pediatric Infect Dis Soc 3 (Suppl 1): S36S40.
  37. Howard EJ, Xiong X, Carlier Y, Sosa-Estani S, Buekens P, , 2014. Frequency of the congenital transmission of Trypanosoma cruzi: a systematic review and meta-analysis. BJOG 121: 2233.
  38. Klein N, Hurwitz I, Durvasula R, , 2012. Globalization of Chagas disease: a growing concern in nonendemic countries. Epidemiol Res Int 2012: 12.
  39. Sanchez Negrette O, Mora MC, Basombrio MA, , 2005. High prevalence of congenital Trypanosoma cruzi infection and family clustering in Salta, Argentina. Pediatrics 115: e668e672.
  40. Herrador Z, Rivas E, Gherasim A, Gomez-Barroso D, Garcia J, Benito A, Aparicio P, , 2015. Using hospital discharge database to characterize Chagas disease evolution in Spain: there is a need for a systematic approach towards disease detection and control. PLoS Negl Trop Dis 9: e0003710.
  41. Roca C, Pinazo MJ, Lopez-Chejade P, Bayo J, Posada E, Lopez-Solana J, Gallego M, Portus M, Gascon J, Chagas-Clot Research Group; , 2011. Chagas disease among the Latin American adult population attending in a primary care center in Barcelona, Spain. PLoS Negl Trop Dis 5: e1135.
  42. Tarleton RL, Curran JW, , 2012. Is Chagas disease really the “new HIV/AIDS of the Americas”? PLoS Negl Trop Dis 6: e1861.
  43. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, Postan M, Armenti A, , 2006. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 144: 724734.
  44. Jackson Y, Castillo S, Hammond P, Besson M, Brawand-Bron A, Urzola D, Gaspoz JM, Chappuis F, , 2012. Metabolic, mental health, behavioural and socioeconomic characteristics of migrants with Chagas disease in a non-endemic country. Trop Med Int Health 17: 595603.
  45. Pereira PC, Navarro EC, , 2013. Challenges and perspectives of Chagas disease: a review. J Venom Anim Toxins Incl Trop Dis 19: 34.
  46. Franco-Paredes C, Bottazzi ME, Hotez PJ, , 2009. The unfinished public health agenda of Chagas disease in the era of globalization. PLoS Negl Trop Dis 3: e470.
  47. Jackson Y, 2010. Prevalence, clinical staging and risk for blood-borne transmission of Chagas disease among Latin American migrants in Geneva, Switzerland. PLoS Negl Trop Dis 4: e592.
  48. Rassi A, Jr., 2007. Implantable cardioverter-defibrillators in patients with Chagas heart disease: misperceptions, many questions and the urgent need for a randomized clinical trial. J Cardiovasc Electrophysiol 18: 12411243.
  49. Ramsey JM, Elizondo-Cano M, Sanchez-Gonzalez G, Pena-Nieves A, Figueroa-Lara A, , 2014. Opportunity cost for early treatment of Chagas disease in Mexico. PLoS Negl Trop Dis 8: e2776.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.17-0818
Loading
/content/journals/10.4269/ajtmh.17-0818
Loading

Data & Media loading...

Supplementary Data

Supplemental Text, Tables, and Figures

  • Received : 19 Oct 2017
  • Accepted : 02 Mar 2018

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error